Top Court Won't Consider Mylan's Patent Battle Over Amrix
The U.S. Supreme Court on Monday declined Mylan Pharmaceuticals Inc.'s request to review a Federal Circuit decision upholding Cephalon Inc.'s patents for the muscle relaxant Amrix, which Mylan argued allows for...To view the full article, register now.
Already a subscriber? Click here to view full article